Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
INTERLEUKIN-12 INCREASES BISPECIFIC-ANTIBODY-MEDIATED NATURAL-KILLER-CELL CYTOTOXICITY AGAINST HUMAN TUMORS
Autore:
SAHIN U; KRAFTBAUER S; OHNESORGE S; PFREUNDSCHUH M; RENNER C;
Indirizzi:
UNIV SAARLAND,SCH MED,MED KLIN 1,OSCAR ORTH STR D-66421 HOMBURG SAAR GERMANY UNIV SAARLAND,SCH MED,MED KLIN 1 D-66421 HOMBURG SAAR GERMANY
Titolo Testata:
Cancer immunology and immunotherapy
fascicolo: 1, volume: 42, anno: 1996,
pagine: 9 - 14
SICI:
0340-7004(1996)42:1<9:IIBN>2.0.ZU;2-I
Fonte:
ISI
Lingua:
ENG
Soggetto:
STIMULATORY FACTOR NKSF; CYTOLYTIC ACTIVITY; LYMPHOCYTES; RECEPTOR; LYSIS; FC; ACTIVATION; BLOOD;
Keywords:
BISPECIFIC ANTIBODIES; COLORECTAL CARCINOMA; HODGKINS DISEASE; IL-12;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
27
Recensione:
Indirizzi per estratti:
Citazione:
U. Sahin et al., "INTERLEUKIN-12 INCREASES BISPECIFIC-ANTIBODY-MEDIATED NATURAL-KILLER-CELL CYTOTOXICITY AGAINST HUMAN TUMORS", Cancer immunology and immunotherapy, 42(1), 1996, pp. 9-14

Abstract

The combination of CD16/CD30 bispecific monoclonal antibodies (bi-mAb) and unstimulated human resting natural killer (NK) cells can cure about 50% of mice with severe combined immunodeficiency (SCID) bearing subcutaneously growing established Hodgkin's lymphoma. As interleukin-2(IL-2) and IL-12 have been shown to increase NK cell activity, we tested the capacity of these cytokines to increase bi-mAb-mediated NK cell cytotoxicity against two types of human tumors (Hodgkin's disease and colorectal carcinoma). Unstimulated NK cells needed a three- to five-times higher antibody concentration than cytokine-stimulated NK cellsto exert similar levels of bi-mAb-mediated cytotoxicity. The augmented tumor cell lysis was achieved with IL-12 at considerably lower concentrations than with IL-2 and was associated with a significantly increased bi-mAb-mediated intracellular Ca2+ mobilization. The efficiency of IL-12 in this setting together with its low toxicity make it the ideal candidate for a combination therapy with NK-cell-activating bi-mAb in human tumors that are resistant to standard treatment.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/03/20 alle ore 04:46:06